Functional constipation (FC) in children often requires medical treatment, including pharmacotherapy. Conventional laxatives such as magnesium oxide, sodium picosulfate, lactulose, and carmellose sodium have been used for many years. However, these drugs are often ineffective for patients with intractable FC, requiring continual transanal treatments such as glycerin enemas or bisacodyl suppositories.
is the first clinical research on the use of Mc to treat FC in children.
MATERIALS AND METHODS

Subjects
This was a single-center retrospective cross-sectional study carried out at the Division of Pediatrics in Tohoku Medical and Pharmaceutical University. Thirty-six patients, who conformed to Rome criteria for FC and visited our center for two years from June 2016, were recruited in the study [2] .
An exclusion criterion was secondary constipation due to congenital, anatomical, endocrinal, or metabolic disorders.
Thirty-five patients were finally registered in the study except for one patient with lumbar lipoma and spina bifida.
The included patients were divided into two groups by an informed consent according to the administration of Mc.
We recommended the administration of Mc to the patients with the symptoms of FD positively. In Mc group, comprising eighteen patients with agreement of the administration, Mc (0.3 mg/kg/day in two divided doses) was added after the conventional laxatives were ineffective [3] . In a control group, comprising seventeen patients without the agreement, the conventional laxatives were used only. The conventional laxatives were administered according to weight (kg), according to a previously published guideline [4] and medical user's manuals. We obtained informed consent for all patients from patients and their caregivers. The Committee on Ethical Affairs in our center judged that the study did not have any ethical problems, because all procedures had been performed under the Health Care Services provided by Health Insurance in Japan (registry number: 2018-2-060).
The treatment was estimated as effective when the patient did not meet Rome IV FC criteria [4, 5] for more than four weeks {e.g., bowel movement frequency was more than 3 days per week (BMF) or stool consistency was consistently higher than type 3 on the Bristol stool form scale (BSFS)}. De-escalation of the laxatives including Mc was performed in a step-wise manner and was started when the treatment was effective.
Complete remission (CR) was defined as a laxative-free status for more than 4 weeks based on our previous clinical study and a previous article [5, 6] .
Methods
All data were extracted from the health records retrospectively.
Survey items were sex, height (cm), weight (kg), age in months at first visit, experiencing ineffective conventional laxative treatments prior to visiting our center (EICLT), BMF and median BSFS in the last month, treatment duration until CR at our center, requiring the continual transanal treatments, and percentage achieving CR.
Analysis of the collected data was performed using "EZR" freesoftware program [7] . The Mann-Whitney U test was used to compare data: age in months at the first visit, height, weight, BMF, BSFS, dosage of laxatives including Mc, and treatment duration. A 2 × 2 Chi-square-test was used to analyze categorical data including sex, EICLT, and CR. P values <0.05
were considered significant.
RESULTS
The patient backgrounds prior to visiting our center are shown in (Table 1 ). was cited to support this point [9] . Mc is also described in the Japanese guideline for FC in children, but it has no citations supporting the recommendation [4] .
BSFS, not BMF, provides a severity in mild FC [10] . Long disease duration by hard stool (low grade BSFS: 1 or 2) induces a disturbance in the colon wall, and an impaired neuronal response for bowel movement should be to decrease BMF due to delay of colonic transit time [11] . This vicious cycle leads to intractable FC, in which BMF provides the severity of FC as effectively as BSFS [4, 11] . It was suggested that Mc group should show more intractable FC than the control group according to BMF. In animal studies, it was shown that the prokinetic activity of Mc is effective for constipation [12, 13] . Mc was also shown to repair injured enteric neurons in a mouse [14] . In humans, it was shown that Mc enhanced rectosigmoid sensorimotor function in patients with constipation-type irritable bowel syndrome [15] . Therefore, in pediatric FC patients, Mc might also induce spontaneous bowel movements and increase BMF.
We attempted to prove the efficacy. All patients with more intractable FC than the control group, Mc group, eventually achieved CR by the improvement of BMF in ( 
